Marcel Miedouge
Marcel Miedouge has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
Jacques Izopet
3 shared publications- Florence Abravanel
Laboratory of Virology, Institut Fédératif de Biologie, CHU Toulouse, 31300 Toulouse, France
2 shared publications Karine Saune
2 shared publicationsAgnès Bailly
1 shared publication- Alexandre Aversenq
CHU Toulouse, Hôpital Purpan, Laboratoire de Virologie, National Reference Center for Hepatitis E, 31300 Toulouse, France
1 shared publication Colette Lalanne
1 shared publication
Latest Publications
- Open Access
Diagnostic Performance of an Automated System for Assaying Anti-Hepatitis E Virus Immunoglobulins M and G Compared with a Conventional Microplate Assay
To evaluate the diagnostic performance of the Liaison® Murex anti-HEV IgM and IgG assays running on the Liaison® instrument and compare the results with those obtained with Wantai HEV assays. We tested samples collected in immunocompetent and immunocompromised patients during the acute (HEV RNA positive, anti-HEV IgM positive) and the post-viremic phase (HEV RNA negative, anti-HEV IgM positive) of infections. The specificity was assessed by testing HEV RNA negative/anti-HEV IgG-IgM negative samples. The clinical sensitivity of the Liaison® IgM assay was 100% for acute-phase samples (56/56) and 57.4% (27/47) for post-viremic samples from immunocompetent patients. It was 93.8% (30/32) for acute-phase (viremic) samples and 71%% (22/31) for post-viremic samples from immunocompromised patients. The clinical sensitivity of the Liaison® IgG assay was 100% for viremic samples (56/56) and 94.6% (43/47) for post-viremic samples from immunocompetent patients. It was 84.3% (27/32) for viremic samples and 93.5% (29/31) for post-viremic samples from immunocompromised patients. Specificity was very high (>99%) in both populations. We checked the limit of detection stated for the Liaison® IgG assay (0.3 U/mL). The clinical performance of the Liaison® ANTI-HEV assays was good. These rapid, automated assays for detecting anti-HEV antibodies will greatly enhance the arsenal for diagnosing HEV infections.
Open AccessDiagnostic Performance of an Automated System for Assaying Anti-Hepatitis E Virus Immunoglobulins M and G Compared with a Conventional Microplate Assay
To evaluate the diagnostic performance of the Liaison® Murex anti-HEV IgM and IgG assays running on the Liaison® instrument and compare the results with those obtained with Wantai HEV assays. We tested samples collected in immunocompetent and immunocompromised patients during the acute (HEV RNA positive, anti-HEV IgM positive) and the post-viremic phase (HEV RNA negative, anti-HEV IgM positive) of infections. The specificity was assessed by testing HEV RNA negative/anti-HEV IgG-IgM negative samples. The clinical sensitivity of the Liaison® IgM assay was 100% for acute-phase samples (56/56) and 57.4% (27/47) for post-viremic samples from immunocompetent patients. It was 93.8% (30/32) for acute-phase (viremic) samples and 71%% (22/31) for post-viremic samples from immunocompromised patients. The clinical sensitivity of the Liaison® IgG assay was 100% for viremic samples (56/56) and 94.6% (43/47) for post-viremic samples from immunocompetent patients. It was 84.3% (27/32) for viremic samples and 93.5% (29/31) for post-viremic samples from immunocompromised patients. Specificity was very high (>99%) in both populations. We checked the limit of detection stated for the Liaison® IgG assay (0.3 U/mL). The clinical performance of the Liaison® ANTI-HEV assays was good. These rapid, automated assays for detecting anti-HEV antibodies will greatly enhance the arsenal for diagnosing HEV infections.
- 1 January 2011
- Published by Elsevier in Journal of Clinical Virology
- Vol. 50 (1) , 57-60
Analytical sensitivity of four HIV combined antigen/antibody assays using the p24 WHO standard
- 1 January 2011
- Published by Elsevier in Journal of Clinical Virology
- Vol. 50 (1) , 57-60
Analytical sensitivity of four HIV combined antigen/antibody assays using the p24 WHO standard
- 1 May 2010
- Published by Elsevier in Journal of Clinical Virology
- Vol. 48 (1) , 18-21
Analytical evaluation of HCV core antigen and interest for HCV screening in haemodialysis patients
- 1 May 2010
- Published by Elsevier in Journal of Clinical Virology
- Vol. 48 (1) , 18-21
Analytical evaluation of HCV core antigen and interest for HCV screening in haemodialysis patients
- 1 February 2010
- Published by Elsevier in Revue Francophone des Laboratoires
- Vol. 2010 (419) , 65-68
Une expérience pratique d’accréditation en virologie
- 1 February 2010
- Published by Elsevier in Revue Francophone des Laboratoires
- Vol. 2010 (419) , 65-68
Une expérience pratique d’accréditation en virologie
- 28 February 2009
- Published by Elsevier in Journal of Clinical Virology
- Vol. 44 (2) , 134-137
Laboratory evaluation of the UniCel DxI 800 analyser (Beckman Coulter) for detecting HBV and HCV serological markers
- 28 February 2009
- Published by Elsevier in Journal of Clinical Virology
- Vol. 44 (2) , 134-137
Laboratory evaluation of the UniCel DxI 800 analyser (Beckman Coulter) for detecting HBV and HCV serological markers
- 25 March 2003
- Published by Springer Nature in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 22 (4) , 246-248
Screening for Hepatitis B Virus DNA in Serum of Organ Donors and Renal Transplant Recipients
In order to determine the impact of screening potential organ donors for hepatitis B virus DNA using a standardized test, the serum of 145 donor candidates was tested. All of the candidates were negative for hepatitis B virus DNA, but the status of one donor was doubtful for hepatitis B virus surface antigen and seven donors tested positive for hepatitis B virus core antibody without hepatitis B virus surface antigen. Nine transplant recipients tested positive for hepatitis B virus surface antibody; they were given kidneys from the donor with a doubtful hepatitis B virus surface antigen result and from four of the seven donors who tested positive for hepatitis B core antibody. Follow-up revealed no case of hepatitis B transmission. In this study, screening for hepatitis B virus DNA was useful and did not lead to donor organ shortage. Patients with hepatitis B virus surface antibodies can safely be given kidneys from donors who are positive for hepatitis B core antibody but negative for hepatitis B virus DNA.
- 25 March 2003
- Published by Springer Nature in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 22 (4) , 246-248
Screening for Hepatitis B Virus DNA in Serum of Organ Donors and Renal Transplant Recipients
In order to determine the impact of screening potential organ donors for hepatitis B virus DNA using a standardized test, the serum of 145 donor candidates was tested. All of the candidates were negative for hepatitis B virus DNA, but the status of one donor was doubtful for hepatitis B virus surface antigen and seven donors tested positive for hepatitis B virus core antibody without hepatitis B virus surface antigen. Nine transplant recipients tested positive for hepatitis B virus surface antibody; they were given kidneys from the donor with a doubtful hepatitis B virus surface antigen result and from four of the seven donors who tested positive for hepatitis B core antibody. Follow-up revealed no case of hepatitis B transmission. In this study, screening for hepatitis B virus DNA was useful and did not lead to donor organ shortage. Patients with hepatitis B virus surface antibodies can safely be given kidneys from donors who are positive for hepatitis B core antibody but negative for hepatitis B virus DNA.